Value of Red Blood Cell Distribution Width and Fibrinogen Level for Evaluation of the Therapeutic Efficacy and Prognosis in Patients with Diffuse Large B-Cell Lymphoma.
10.7534/j.issn.1009-2137.2020.01.026
- Author:
Xin WANG
1
;
Chong-Yang WU
1
;
Peng-Yun ZENG
1
;
Liang-Liang LI
1
;
Cheng-Cheng MA
1
;
Xue XIANG
1
;
Yan-Qing LI
1
;
Ye CHAI
2
,
3
Author Information
1. Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.
2. Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China,E-mail: papillon2009@
3. com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):153-159
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the value of red blood cell distribution width (RDW) and fibrinogen (Fib) level for the evaluation of therapeutic efficacy and prognosis in patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:The relationship between RDW/Fib at initial diagnosis and efficacy and the clinical outcome was retro-spectively analyzed based on the study of 105 patients with DLBCL. The patients were divided into two groups: low RDW group (≤15%) and high RDW group (>15%), low Fib group (Fib≤4 g/L) and high Fib group (Fib>4 g/L) according to the normal values of RDW and Fib. Therapeutic efficacy, overall survival (OS) time and progression free survival (PFS) time were compared between two groups. The correlation between each factors and efficacy, prognosis was analyzed by univariate and multivariate regression.
RESULTS:The therapeutic efficacy (P<0.001), OS time(P=0.004), and PFS time(P=0.007) were poorer in the high RDW group as compared with the low RDW group. The efficacy (P=0.015) and PFS time(P=0.04) were poorer in the high Fib group as compared with the low Fib group. Multivariate analysis showed that high RDW was the independent risk factor for efficacy of DLBCL patients (OR=3.394, 95% CI 1.093-10.539, P=0.035).
CONCLUSION:High RDW and high Fib associate with poor efficacy in DLBCL patients.
